Month: September 2026

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to report the voting results from its Annual General Meeting of shareholders (the “Meeting”) held earlier today.

A total of 26,439,140 shares were represented in person or by proxy at the Meeting, constituting approximately 39.1% shares represented of the Company’s total issued and outstanding Common shares as of the record date, and voted in favour of all matters brought before the Meeting.

Results of Annual General Meeting

The following matters put forward before shareholders for consideration and approval as set out in Rubicon Organics’ management information circular dated August 19^th, 2026 (the “Circular”) were approved by the shareholders:

• Setting the number of directors of the Company at five;
• Electing Doris Bitz, Jesse McConnell, John Pigott, Margaret Brodie, and Michael Detlefsen as directors of the Company (together the “Board”) for the ensuing year until the next annual meeting of the Company; and
• Appointing PricewaterhouseCoopers LLP as the Company’s auditors for the ensuing year with the Company’s directors authorized to fix their remuneration.

Question	Yes		No		Abstain
Number of Directors at Five (5)	99.8%		0.2%		–
Elect as Director, Doris Bitz	99.2%		–		0.8%
Elect as Director, Jesse McConnell	98.7%		–		1.3%
Elect as Director, John Pigott	92.8%		–		7.2%
Elect as Director, Margaret Brodie	98.6%		–		1.4%
Elect as Director, Michael Detlefsen	93.6%		–		6.4%
Appointment of Auditor	100.0%		–		–

Board Departures

As Len Boggio, Ian Gordon, and Karen Proud did not stand for re-election at the Meeting, they have retired from the Board effective today.

“On behalf of Rubicon Organics and the Board, I would like to thank Len, Ian, and Karen for their dedicated service and valuable contributions to the Company,” said Doris Bitz, Chair of the Board. “Their guidance, experience, and commitment have supported Rubicon Organics through important stages of its development, and we wish each of them the very best in their future endeavours.”

Engagement of Atrium Research Corporation

Rubicon Organics has renewed the services of Atrium Research Corporation (“Atrium”), an independent third-party, to provide research services. Atrium will receive $10,500 per quarter for 12 months beginning on October 1st, 2026. This engagement is subject to TSX-V approval. Atrium and the Company are arm’s-length parties, and neither Atrium nor its insiders holds any shares or options to purchase shares in the issued and outstanding capital of the Company.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

CONTACT INFORMATION

Margaret Brodie
Chief Executive Officer
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “may”, “could”, “would”, “should”, “estimates”, “potential” or variations of such words and similar expressions or statements that certain actions, events or results may, could, would, should or will, occur or be achieved.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding the continued service and contributions of the directors elected at the Meeting; the Company’s ability to benefit from the experience and expertise of its Board; the Board’s ability to provide effective governance and strategic oversight; the continued availability of Atrium’s services on the terms described herein; stable market conditions; the Company’s ability to maintain product quality, supply and production levels; and the Company’s ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the contributions of the directors elected at the Meeting; the Board’s role in supporting the Company’s long-term objectives; the renewal of Atrium’s services for a 12-month period; the Company’s ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company’s production capacity, revenue growth opportunities and strategic initiatives. These risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, competition, regulatory developments, access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., to the Company’s Board of Directors, effective immediately. The appointments bring together two accomplished leaders whose complementary experience spans public service, Medicare Advantage, clinical practice, healthcare policy, and business. Senator Torricelli will serve on the Board’s Audit Committee, and Dr. Miller will serve on its Clinical Committee. The appointments fill the Board’s two previously disclosed vacancies and bring the Board to nine directors.

“Today marks an exciting step forward for Clover, and we are thrilled to welcome Bob and Brian to our Board,” said Andrew Toy, Chief Executive Officer of Clover Health. “Bob brings deep ties to New Jersey communities, experience navigating federal policy, and firsthand knowledge of Clover. Brian combines clinical experience with a national perspective on Medicare payment and technology policy. His insights will help us advance care that improves quality, operates more efficiently, and generates meaningful savings. Together, their experience, judgment, and perspectives will strengthen our Board and reinforce our ability to execute with discipline, grow responsibly, and build lasting value for our members, physicians, and shareholders.”

“From the beginning, we built Clover around the belief that some of the hardest problems in healthcare can be solved by challenging long-held assumptions about how healthcare works and care is delivered,” added Vivek Garipalli, Co-founder of Clover Health and Executive Chairperson of the Board. “As Clover grows, it is important that our Board continues to reflect the complexity of the healthcare system we are working to improve and brings together special individuals who understand it from fundamentally different vantage points. Bob and Brian add tremendous depth across public policy, medicine, Medicare and business, and their perspectives will be invaluable as we drive forward on Clover’s mission to Improve Every Life.”

Senator Torricelli brings a distinctive combination of deep New Jersey roots, national policymaking experience, and firsthand knowledge of Clover. For 20 years, he represented New Jersey in the U.S. House of Representatives and the U.S. Senate, where his committee service included the Senate Finance Committee and work on federal financing for healthcare institutions. Following his congressional career, he founded Rosemont Associates, a business strategy firm, and established Woodrose Properties, a real estate development business. Since 2022, he has served on the board of the Company’s insurance subsidiaries, giving him firsthand familiarity with Clover’s business, mission, and approach to Medicare Advantage. Additionally, Senator Torricelli has served as a director of Glassbridge Enterprises, Inc. since February 2017 and previously served as executive vice president and chief operating officer of Aveta, Inc., a healthcare services company. His experience navigating complex policy and business issues will bring a valuable perspective to Clover’s Board and Audit Committee.

“Through my years living in New Jersey and representing its communities in Congress, I have come to know the challenges many seniors face in accessing high-quality, affordable care,” said Senator Torricelli. “Through my service on Clover’s insurance subsidiary board, I have seen the Company’s commitment to meeting those challenges with an ambitious vision and a practical, technology-driven approach. I am honored to join the Board and excited to contribute to its oversight, support this talented team, and help Clover build lasting value for members and shareholders.”

Dr. Miller brings a rare combination of frontline clinical practice and national Medicare policy leadership. A practicing hospitalist at the Johns Hopkins Hospital, an Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Visiting Fellow at the Hoover Institution, Dr. Miller brings to Clover broad ranging regulatory experience spanning the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, and the Federal Trade Commission. He currently serves as Vice Chairman of the Board of Trustees for the North Carolina State Health Plan and as a Commissioner on the Medicare Payment Advisory Commission (MedPAC), the independent, nonpartisan commission that advises Congress on Medicare payment policy. Board-certified in internal medicine and preventive medicine, Dr. Miller offers a practical perspective on improving care delivery and advancing a more effective Medicare program.

“As a practicing physician, I see every day how much better technology can support clinical practice when it delivers the right information at the point of care,” said Dr. Miller. “Medicare needs models that can improve both convenience and quality for consumers, increase efficiency, and generate savings without adding burden for physicians or patients. Clover is building a differentiated model for Medicare Advantage: flexible and nimble, powered by technology, and close enough to physicians and patients to translate innovation into action. I am delighted to join the Board and look forward to helping Clover advance this approach and deliver a better care experience for people on Medicare.”

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health’s Medicare Advantage plan, we extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and aim to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology’s impact on Medication Adherence, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and in Underserved Populations as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

Investor Relations:
Ryan Schmidt
investors@cloverhealth.com

Press Inquiries:
press@cloverhealth.com

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a domestic energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, today announced that its Interim President, Chief Executive Officer R.T. Dukes and Chief Financial Officer Robert Long, will participate in two upcoming virtual conferences hosted by Lytham Partners and Noble Capital Markets.

Lytham Partners Investor Conference – Fall Event | September 29 – 30, 2026

Management is scheduled to present on Tuesday, September 29, at 12:00 p.m. ET and will host virtual one-on-one meetings with investors on Wednesday, September 30, 2026. Interested parties can register for the event here or view the live presentation by visiting the conference webcast link here.

Noble Capital Markets Emerging Growth Virtual Equity Conference | October 1 – 2, 2026

Management is scheduled to present on Thursday, October 1, 2026, at 10:30 a.m. ET, and will host one-on-one meetings with investors that day. Interested parties can register on Noble’s website at www.nobleconference.com/virtual.

To request a meeting with PEDEVCO’s management team during the conferences, please contact your conference representative or the Company’s investor relations team at PED@elevate-ir.com. After each event, replays of the Company’s presentations will be listed in the investor relations section of its website at www.pedevco.com.

About PEDEVCO Corp.
PEDEVCO Corp. (NYSE American: PED) is a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region. The Company holds over 300,000 net acres, with principal assets in the D-J Basin of southeastern Wyoming and northern Colorado, as well as the Powder River Basin of northeastern Wyoming. PEDEVCO is headquartered in Houston, Texas. More information about PEDEVCO can be found at www.pedevco.com.

Media Contact:
PEDEVCO Corp.
(713) 221-1768
PR@pedevco.com

Investor Relations Contact:
Sean Mansouri, CFA or Laurent Weil
Elevate IR
(720) 330-2829
PED@elevate-ir.com